Skip to main content
Erschienen in: Supportive Care in Cancer 9/2019

07.01.2019 | Original Article

Evaluation of a community-based dental screening program prior to radiotherapy for head and neck cancer: a single-center experience

verfasst von: Elizabeth Waring, Hani Mawardi, Sook Bin Woo, Nathaniel Treister, Danielle N. Margalit, Jennifer Frustino, Alessandro Villa

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Oral toxicities following radiation therapy (RT) for head and neck (HN) cancer can be profound and are associated with poor health outcomes. The Division of Oral Medicine and Dentistry at Brigham and Women’s Hospital and Dana-Farber Cancer Institute therefore implemented a dental evaluation program designed for community-based (CB) dentists to evaluate and treat patients scheduled for HN RT. The aim of this retrospective single-center cohort study was to assess the compliance of CB dentists with this pre-RT dental evaluation program.

Methods

A retrospective analysis of dental evaluations completed by CB dentists from December 2013 to December 2015 was performed. Descriptive statistics were used to determine compliance.

Results

A total of 186 dental evaluations were received. Compliance with completion of dental treatment was as follows: scaling and prophylaxis: 94.5% (172/182); dental restorations: 78.7% (48/61); endodontic therapy: 76.9% (10/13); and dental extractions: 76.9% (30/39). Compliance of CB dentists with all requested components of the pre-RT evaluation and treatment was 77.4% (144/186). The median distance traveled by patients to the CB dentist and to the hospital was 5.2 miles (range 0.03–66.0) and 46.5 miles (range 0.8–1457; p < 0.01), respectively.

Conclusion

In this study, the majority of patients completed their necessary dental treatment in a timely manner by their CB dentist in collaboration with an oral medicine specialist. Given the high compliance of CB dentists, this program could serve as a model for other cancer centers to optimize oral and dental health prior to RT.
Literatur
2.
Zurück zum Zitat Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD (2017) NCCN guidelines insights: head and neck cancers, version 2.2017. J Natl Compr Cancer Netw 15(6):761–770CrossRef Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD (2017) NCCN guidelines insights: head and neck cancers, version 2.2017. J Natl Compr Cancer Netw 15(6):761–770CrossRef
3.
Zurück zum Zitat Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867CrossRefPubMedPubMedCentral Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Brunner M, Gore SM, Read RL, Alexander A, Mehta A, Elliot M, Milross C, Boyer M, Clark JR (2015) Head and neck multidisciplinary team meetings: effect on patient management. Head Neck 37(7):1046–1050CrossRefPubMed Brunner M, Gore SM, Read RL, Alexander A, Mehta A, Elliot M, Milross C, Boyer M, Clark JR (2015) Head and neck multidisciplinary team meetings: effect on patient management. Head Neck 37(7):1046–1050CrossRefPubMed
5.
Zurück zum Zitat Friedland PL, Bozic B, Dewar J, Kuan R, Meyer C, Phillips M (2011) Impact of multidisciplinary team management in head and neck cancer patients. Br J Cancer 104(8):1246–1248CrossRefPubMedPubMedCentral Friedland PL, Bozic B, Dewar J, Kuan R, Meyer C, Phillips M (2011) Impact of multidisciplinary team management in head and neck cancer patients. Br J Cancer 104(8):1246–1248CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Kelly SL, Jackson JE, Hickey BE, Szallasi FG, Bond CA (2013) Multidisciplinary clinic care improves adherence to best practice in head and neck cancer. Am J Otolaryngol 34(1):57–60CrossRefPubMed Kelly SL, Jackson JE, Hickey BE, Szallasi FG, Bond CA (2013) Multidisciplinary clinic care improves adherence to best practice in head and neck cancer. Am J Otolaryngol 34(1):57–60CrossRefPubMed
8.
Zurück zum Zitat Jensen SB et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 18(8):1061–1079CrossRefPubMed Jensen SB et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 18(8):1061–1079CrossRefPubMed
9.
Zurück zum Zitat Nadella KR, Kodali RM, Guttikonda LK, Jonnalagadda A (2015) Osteoradionecrosis of the jaws: clinico-therapeutic management: a literature review and update. J Maxillofac Oral Surg 14(4):891–901CrossRefPubMedPubMedCentral Nadella KR, Kodali RM, Guttikonda LK, Jonnalagadda A (2015) Osteoradionecrosis of the jaws: clinico-therapeutic management: a literature review and update. J Maxillofac Oral Surg 14(4):891–901CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Margalit DN, Losi SM, Tishler RB, Schoenfeld JD, Ann Fugazzotto J, Stephens J, Cebulski AL, Hammerstrand EL, Ma L, Lopes HM, Haddad RI, Treister NS, Frustino JL (2015) Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract 11(2):151–154CrossRefPubMed Margalit DN, Losi SM, Tishler RB, Schoenfeld JD, Ann Fugazzotto J, Stephens J, Cebulski AL, Hammerstrand EL, Ma L, Lopes HM, Haddad RI, Treister NS, Frustino JL (2015) Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract 11(2):151–154CrossRefPubMed
11.
Zurück zum Zitat Lockhart PB, Clark J (1994) Pretherapy dental status of patients with malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 77(3):236–241CrossRefPubMed Lockhart PB, Clark J (1994) Pretherapy dental status of patients with malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 77(3):236–241CrossRefPubMed
12.
Zurück zum Zitat Jham BC, Reis PM, Miranda EL, Lopes RC, Carvalho AL, Scheper MA, Freire AR (2008) Oral health status of 207 head and neck cancer patients before, during and after radiotherapy. Clin Oral Investig 12(1):19–24CrossRefPubMed Jham BC, Reis PM, Miranda EL, Lopes RC, Carvalho AL, Scheper MA, Freire AR (2008) Oral health status of 207 head and neck cancer patients before, during and after radiotherapy. Clin Oral Investig 12(1):19–24CrossRefPubMed
13.
Zurück zum Zitat Rosales AC et al (2009) Dental needs in Brazilian patients subjected to head and neck radiotherapy. Braz Dent J 20(1):74–77CrossRefPubMed Rosales AC et al (2009) Dental needs in Brazilian patients subjected to head and neck radiotherapy. Braz Dent J 20(1):74–77CrossRefPubMed
14.
Zurück zum Zitat Brennan MT, Treister NS, Sollecito TP, Schmidt BL, Patton LL, Mohammadi K, Long Simpson L, Voelker H, Hodges JS, Lalla RV (2017) Dental disease before radiotherapy in patients with head and neck cancer: Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients. J Am Dent Assoc 148(12):868–877CrossRefPubMedPubMedCentral Brennan MT, Treister NS, Sollecito TP, Schmidt BL, Patton LL, Mohammadi K, Long Simpson L, Voelker H, Hodges JS, Lalla RV (2017) Dental disease before radiotherapy in patients with head and neck cancer: Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients. J Am Dent Assoc 148(12):868–877CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Jones AP, Haynes R, Sauerzapf V, Crawford SM, Zhao H, Forman D (2008) Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer 44(7):992–999CrossRefPubMed Jones AP, Haynes R, Sauerzapf V, Crawford SM, Zhao H, Forman D (2008) Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer 44(7):992–999CrossRefPubMed
16.
Zurück zum Zitat Lightfoot N, Steggles S, Gauthier-Frohlick D, Arbour-Gagnon R, Conlon M, Innes C, Bonsawin L, Merali H (2005) Psychological, physical, social, and economic impact of travelling great distances for cancer treatment. Curr Oncol 12(4):1–7 Lightfoot N, Steggles S, Gauthier-Frohlick D, Arbour-Gagnon R, Conlon M, Innes C, Bonsawin L, Merali H (2005) Psychological, physical, social, and economic impact of travelling great distances for cancer treatment. Curr Oncol 12(4):1–7
Metadaten
Titel
Evaluation of a community-based dental screening program prior to radiotherapy for head and neck cancer: a single-center experience
verfasst von
Elizabeth Waring
Hani Mawardi
Sook Bin Woo
Nathaniel Treister
Danielle N. Margalit
Jennifer Frustino
Alessandro Villa
Publikationsdatum
07.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4626-y

Weitere Artikel der Ausgabe 9/2019

Supportive Care in Cancer 9/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.